The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.
Genpact (G) is a quality investment with strong profitability, low debt, and consistent growth. Its solid financial health and reasonable valuation make it ideal for long-term investors.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
The US dollar has bounced back this morning, and this has kept the EUR/USD under mild pressure, while verbal jawboning in Japan hasn’t helped to stop the yen from sliding to new multi-month lows against the dollar.
Cotton price action is down 55 to 84 points on Wednesday morning. Futures closed the Tuesday session with losses of 35 to 43 points. Crude oil futures were up 89 cents/barrel to $61.02 on the day, with the US dollar index $0.107 lower to $99.355. The...
Lean hog futures posted mixed Tuesday action with contracts down 42 to up 40 cents. Preliminary open interest was down 6,796 contracts on Tuesday, with much of that coming via December (11,027). USDA’s national base hog price from Tuesday afternoon w...
Wheat is showing losses across the three exchanges on Wednesday morning, as bulls are failing to hold recent ground gained. The wheat complex saw mixed trade on Tuesday, with spring wheat leading the way higher. CBT soft red wheat futures were fracti...
Corn price action is showing fractional losses so far on Wednesday morning. The corn market saw Tuesday gains of 2 to 3 cents across most contracts at the close. Preliminary open interest showed some exiting of December, down 44,027 contracts, with t...
Soybeans are trading with slight fractional gains on Wednesday. Futures closed Tuesday with contracts down 1 to 3 cents. Open interest was up 7,135 contracts on Tuesday, with the front 2 contracts seeing some decline. There was another 29 deliveries...
Live cattle futures were down 60 cents to $1.35 at the close. Preliminary open interest dropped 2,522 contracts, with December down 8,675 contracts and Feb up 4,727 contracts. Last week’s cash trade was reported at $225-230 in the north, with $230-23...
Ovid Therapeutics announces CEO succession plan and key pipeline progress for epilepsy drug OV329 and KCC2 activators, backed by a strong cash position.
Humacyte (HUMA) missed Q3 revenue estimates but delivered a smaller-than-expected loss per share. The stock rose as investors focused on its pipeline progress toward key regulatory milestones.
Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™.
Abeona Therapeutics beat Q3 EPS estimates but missed on revenue. The stock fell as investors focus on the delayed launch of its new gene therapy, ZEVASKYN.
Agnico Eagle Mines (AEM) stock shows a powerful mix of strong technical uptrend and accelerating fundamental growth, making it a top pick for momentum investors.
Caesarstone (CSTE) Q3 2025 results show revenue beat estimates, but earnings missed with a wider loss. The company announced a major restructuring to cut costs.
Although PulteGroup has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Joshua Brown picks Phillips 66 as a breakout is in progress, citing the company's strong earnings. Shannon Saccocia chooses iShares MSCI Emerging Markets ETF.
